Group 1: Earnings Performance - Cardinal Health reported quarterly earnings of $2.08 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and up from $1.84 per share a year ago, representing an earnings surprise of +2.46% [1] - The company posted revenues of $60.16 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.84%, but up from $59.87 billion year-over-year [2] Group 2: Stock Performance and Outlook - Cardinal shares have increased by approximately 33.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is $2.17 on revenues of $57.99 billion, and for the current fiscal year, it is $9.21 on revenues of $248.27 billion [7] Group 3: Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Pro-Dex, Inc., another company in the same industry, is expected to report quarterly earnings of $0.47 per share, reflecting a year-over-year change of +2.2% [9]

Core Insights - DarioHealth Corp. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and a decline from earnings of $0.06 per share a year ago, indicating an earnings surprise of -9.09% [1] - The company generated revenues of $5.37 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 22.19% and down from $6.26 million year-over-year [2] - DarioHealth shares have decreased by approximately 36% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.07 on revenues of $8.52 million, and for the current fiscal year, it is -$0.32 on revenues of $32.24 million [7] Industry Context - The Medical - Instruments industry, to which DarioHealth belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook could significantly impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Financial Performance - Madison Square Garden (MSGS) reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of +83.33% [1] - The company posted revenues of $203.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 23.10%, although this is a decline from year-ago revenues of $227.25 million [2] - Over the last four quarters, Madison Square Garden has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Madison Square Garden shares have declined approximately 10.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$1.01 on revenues of $56.2 million, and for the current fiscal year, it is $0.79 on revenues of $1.04 billion [7] Industry Context - The Leisure and Recreation Services industry, to which Madison Square Garden belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Madison Square Garden's stock performance [5]

Core Viewpoint - Sonida Senior Living (SNDA) reported a quarterly loss of $0.16 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.78, indicating a positive earnings surprise of +79.49% [1] Financial Performance - The company posted revenues of $82.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.31% and showing an increase from $70.21 million in the same quarter last year [2] - Over the last four quarters, Sonida Senior Living has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Sonida Senior Living shares have increased by approximately 5.6% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $85.06 million, and for the current fiscal year, it is -$3.06 on revenues of $333.9 million [7] - The trend of earnings estimate revisions for Sonida Senior Living was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Services industry, to which Sonida Senior Living belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - U.S. Cellular reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and up from $0.20 per share a year ago [1] - The earnings surprise was +9.09%, while the previous quarter saw a surprise of -43.24% with actual earnings of $0.21 per share against an expectation of $0.37 [2] - The company posted revenues of $916 million for the quarter, surpassing the Zacks Consensus Estimate by 1.31%, but down from $927 million year-over-year [3] Market Performance - U.S. Cellular shares have increased approximately 18.4% since the beginning of the year, compared to an 8.6% gain for the S&P 500 [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $899.42 million, and for the current fiscal year, it is $0.61 on revenues of $3.64 billion [8] - The Wireless National industry is ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [9]

Group 1: Financial Performance - Standard BioTools reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $41.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $37.21 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $40.7 million, and for the current fiscal year, it is -$0.14 on revenues of $169.3 million [7] Group 2: Market Performance - Standard BioTools shares have declined approximately 25.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company has surpassed consensus revenue estimates three times over the last four quarters, but has only exceeded consensus EPS estimates once in the same period [2][1] Group 3: Industry Outlook - The Medical Info Systems industry, to which Standard BioTools belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Company Performance - Maravai LifeSciences Holdings, Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -33.33% [1] - The company posted revenues of $47.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.23%, and a significant decline from year-ago revenues of $73.4 million [2] - Over the last four quarters, Maravai has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Maravai LifeSciences shares have declined approximately 59.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $50.74 million, and for the current fiscal year, it is -$0.24 on revenues of $196.21 million [7] Industry Outlook - The Medical - Products industry, to which Maravai belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Maravai's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +22.22% [1] - The company posted revenues of $10 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.62%, and a decline from year-ago revenues of $20.1 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Movement and Outlook - Shares of Aquestive Therapeutics have increased by approximately 9.6% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $12.33 million, and for the current fiscal year, it is -$0.72 on revenues of $45.27 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Company Performance - Assertio reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.04 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $29.22 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.55%, but down from $31.13 million in the same quarter last year [2] - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - Assertio shares have declined approximately 16.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $31.2 million, and for the current fiscal year, it is -$0.27 on revenues of $117.81 million [7] Industry Context - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Assertio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Company Performance - Aris Water Solutions reported quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.24 per share, representing an earnings surprise of -20.83% [1] - The company posted revenues of $124.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.61%, compared to year-ago revenues of $101.12 million [2] - Over the last four quarters, Aris Water Solutions has surpassed consensus revenue estimates four times, but has only exceeded EPS estimates once [2] Stock Performance - Aris Water Solutions shares have lost about 1.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current Zacks Rank for Aris Water Solutions is 5 (Strong Sell), indicating expected underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.28 on revenues of $122.99 million, and for the current fiscal year, it is $1.04 on revenues of $485.6 million [7] - The outlook for the Waste Removal Services industry, where Aris Water Solutions operates, is currently in the bottom 28% of Zacks industries, which may impact stock performance [8]